ARS Pharmaceuticals appoints new CEO
Seeking Alpha ·
ARS Pharmaceuticals ( SPRY ) appointed Donn Casale as chief executive officer and director, effective July 7, 2026, succeeding co-founder Richard Lowenthal. Richard Lowenthal stepped down as an employee and officer of the company, effective July 6, 2026.
DYAX Investor Sentiment
Bullish (Long) 41% · Bearish (Short) 59%
485 participants
Related News
- Lockheed Martin wins two U.S. defense contracts worth over $607M
- Frazier Healthcare Partners to acquire MatrixCare from ResMed
- Bavaria's Minister-President warns of overregulation regarding AI
- Oklahoma sues Allstate, alleging underpayment of damage claims
- Travel stocks extend losses to fifth session amid higher oil prices
- Rivian Is Raising Around $1.5 Billion By Offering 75 Million Shares. Here’s Why the Stock Is Tanking.